Skip to navigation menu Skip to content
Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

Cancer – SC-4016: Phase 1 and 2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

Condition or Therapy:

Solid tumors 

Category:

Cancer and Blood Disorders

What is the goal of this study?

This is a multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients with NTRK fusion cancers treated with a prior TRK inhibitor.

Who can join the study?

This study is for patients with relapsed or refractory solid tumors that are 1 month old or older.

What will happen if my child takes part in this study?

You can read the complete study protocol on clinicaltrials.gov.

Who can I contact for more information?

For more information, call the study team at 206-884-1149 or send us an email.


Study Location(s):

Seattle Children's Hospital campus 

Principal Investigator:

Dr. Katie Albert